Evidence map›Paper›PMID 31029146›Full record

ArticleCardiovascular diabetology2019

The association between fasting plasma glucose and glycated hemoglobin in the prediabetes range and future development of hypertension.

Mika Geva, Gadi Shlomai, Anat Berkovich, Elad Maor, Avshalom Leibowitz, Alexander Tenenbaum, Ehud Grossman

Open access · goldAbstract read
In one paragraph

Article in Cardiovascular diabetology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.

0numbers the graph read from it
0cells of the map it votes in
33citing papers in PubMed
5.1field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

33 citing papers in PubMed, 61 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Hypertension in diabetes.Pediatric nephrology (Berlin, Germany) · 2024
    Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Mika GevaDepartment of Internal Medicine D, Chaim Sheba Medical Center, Ramat Gan, Israel.
Gadi ShlomaiDepartment of Internal Medicine D, Chaim Sheba Medical Center, Ramat Gan, Israel.
Anat BerkovichSackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.
Elad MaorSackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.
Avshalom LeibowitzDepartment of Internal Medicine D, Chaim Sheba Medical Center, Ramat Gan, Israel.
Alexander TenenbaumSackler School of Medicine, Tel-Aviv University, Tel Aviv-Yafo, Israel.
Ehud GrossmanDepartment of Internal Medicine D, Chaim Sheba Medical Center, Ramat Gan, Israel. Ehud.Grossman@sheba.health.gov.il.ORCID 0000-0001-8353-0661
Tel Aviv University · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrediabetes is a well-established risk factor for progression to overt diabetes mellitus (DM), which is in turn associated with development of hypertension (HTN) and vice versa. However, the role of prediabetes and HbA1c in particular as an independent risk factor for the development of hypertension is unclear.

aimIn this current study, we aimed to evaluate the association between both fasting plasma glucose (FPG) and hemoglobin A1c (HbA1c) levels in the prediabetes range and development of HTN among a large cohort of normotensive subjects. DESIGN AND

methodsWe investigated 5016 normotensive participants without DM and other cardiovascular risk factors who were annually screened in a tertiary medical center. Subjects were divided into normoglycemic and prediabetic groups. Normoglycemia was defined as HbA1c < 5.7% and FPG < 100 mg/dl. Prediabetes was defined according to the ADA criteria, i.e., 6.5% > HbA1c ≥ 5.7% or impaired fasting glucose (IFG):126 mg/dl > FPG ≥ 100 mg/dl. Subgroup analysis was made by dividing participants into four groups according to FPG and HbA1C levels, i.e., normoglycemia, impaired HbA1c only, IFG only, and both parameters impaired.

resultsDuring a follow-up of 3.7 ± 2.9 years, 318 (6.3%) subjects developed HTN. A cumulative hazard function for the development of hypertension showed a 2.89-fold ([95% CI 2.19-3.83], p < .0001) increased risk for HTN in the prediabetic population. In a multivariable Cox proportional hazard regression model adjusted to common confounding risk factors for HTN, prediabetes was found to be independently associated with a 1.95-fold ([95%, CI 1.43-2.52] p < .0001) increased risk for hypertension. Impaired HbA1C only was not found to be independently associated with HTN, while IFG only showed a 2.13-fold (95%, [CI 1.46-3.11] p < .0001) increased risk for HTN compared to normoglycemic, and a 2.55-fold ([95% CI 1.85-3.51] p < .0001) increased risk for HTN when both parameters impaired.

conclusionOur study demonstrates that FPG in the prediabetes range, albeit not glycated hemoglobin, is independently and significantly associated with future development of HTN. Therefore, our findings further highlight the pivotal predictive role of IFG for HTN development as opposed to the limited independent role of abnormal HbA1c levels.

Indexed as

Blood PressureAdultBiomarkersBlood GlucoseFastingFemaleGlycated HemoglobinHumansHypertensionIsraelMaleMiddle AgedPrediabetic StatePrognosisRetrospective StudiesRisk AssessmentBiomarkersBlood GlucoseGlycated Hemoglobinhemoglobin A1c protein, humanCardiovascular riskHbA1cHypertensionImpaired fasting glucoseInsulin resistancePrediabetes

Identifiers

PMID31029146
PMCPMC6486972
OpenAlexW2946893712

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.